MOTS-c vs Semaglutide
Related research areas, distinct mechanisms. Live $/mg pricing across every tracked vendor.
Pepticker may earn affiliate commissions (typically 5-20%) from linked vendors. See our Affiliate Disclosure.
Both are studied in metabolic-health research, and both can show up in obesity / glycemic-control conversations. Investigators occasionally compare them when scoping mitochondrial vs. incretin approaches to metabolic dysfunction.
Semaglutide is a GLP-1 receptor agonist with established weight-loss and glycemic-control data. MOTS-c is a mitochondrial-derived exerkine studied for insulin sensitivity and exercise mimicry. They sit in the same broad space but operate via entirely different biology.
MOTS-c
Mitochondrial exerkine
Semaglutide
GLP-1 agonist for metabolic research
About MOTS-c
A 16-residue peptide encoded within the mitochondrial 12S rRNA. Studied as an exercise-mimetic exerkine for metabolic health and longevity.
About Semaglutide
A once-weekly GLP-1 receptor agonist studied for glycemic control and weight loss. Approved as a prescription drug in many jurisdictions; research-peptide vendors supply the compound for laboratory use.